Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ligand Pharmaceuticals Q4 EPS $1.38 Beats $0.66 Estimate, Sales $28.10M Beat $25.72M Estimate

Author: Benzinga Newsdesk | February 27, 2024 08:06am

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $0.66 by 109.09 percent. This is a 1.47 percent increase over earnings of $1.36 per share from the same period last year. The company reported quarterly sales of $28.10 million which beat the analyst consensus estimate of $25.72 million by 9.26 percent. This is a 44.22 percent decrease over sales of $50.38 million the same period last year.

Posted In: LGND


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist